XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue
 6 Months Ended
Jun. 30, 2022
Revenue From Contract With Customer [Abstract]  
Revenue

3.

Revenue

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

As the Company’s performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in Accounting Standards Codification (“ASC”) ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as its patients typically are under no obligation to remain admitted in the Company’s facilities.

The Company disaggregates revenue from contracts with customers by service type and by payor.

The Company’s facilities and services provided by the facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; and residential treatment centers.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

The table below presents total revenue attributed to each category (in thousands):

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Acute inpatient psychiatric facilities

 

$

332,547

 

 

$

281,190

 

 

$

643,295

 

 

$

548,549

 

Specialty treatment facilities

 

 

243,726

 

 

 

227,042

 

 

 

477,366

 

 

 

438,799

 

Residential treatment centers

 

 

75,446

 

 

 

71,722

 

 

 

147,711

 

 

 

140,371

 

Other

 

 

—

 

 

 

2,202

 

 

 

—

 

 

 

5,636

 

Revenue

 

$

651,719

 

 

$

582,156

 

 

$

1,268,372

 

 

$

1,133,355

 

 

The Company receives payments from the following sources for services rendered in its facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); and (iv) individual patients and clients.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of the Company’s facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the condensed consolidated statements of operations. Bad debt expense for the three and six months ended June 30, 2022 and 2021 was not significant.

The following table presents the Company’s revenue by payor type and as a percentage of revenue (in thousands):

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

Amount

 

 

%

 

 

Amount

 

 

%

 

 

Amount

 

 

%

 

 

Amount

 

 

%

 

Commercial

 

$

201,674

 

 

 

30.9

%

 

$

178,846

 

 

 

30.7

%

 

$

396,367

 

 

 

31.2

%

 

$

341,548

 

 

 

30.1

%

Medicare

 

 

96,791

 

 

 

14.8

%

 

 

90,494

 

 

 

15.5

%

 

 

191,373

 

 

 

15.1

%

 

 

176,679

 

 

 

15.6

%

Medicaid

 

 

326,277

 

 

 

50.1

%

 

 

282,416

 

 

 

48.5

%

 

 

626,191

 

 

 

49.4

%

 

 

557,036

 

 

 

49.1

%

Self-Pay

 

 

18,701

 

 

 

2.9

%

 

 

23,434

 

 

 

4.0

%

 

 

38,486

 

 

 

3.0

%

 

 

45,877

 

 

 

4.0

%

Other

 

 

8,276

 

 

 

1.3

%

 

 

6,966

 

 

 

1.3

%

 

 

15,955

 

 

 

1.3

%

 

 

12,215

 

 

 

1.2

%

Revenue

 

$

651,719

 

 

 

100.0

%

 

$

582,156

 

 

 

100.0

%

 

$

1,268,372

 

 

 

100.0

%

 

$

1,133,355

 

 

 

100.0

%

 

Contract liabilities consisted of unearned revenue from CMS’ Accelerated and Advance Payment Program and other advances. In April 2020, the Company received approximately $45 million from CMS’ Accelerated and Advance Payment Program for Medicare providers. Of the $45 million of advance payments received in 2020, the Company repaid approximately $25 million of advance payments during 2021 and made additional repayments of approximately $7 million and $15 million during the three and six month periods ended June 30, 2022, respectively. The Company will continue to repay the remaining balance throughout the rest of 2022. Contract liabilities of $20.2 million and $30.4 million are included in other accrued liabilities at June 30, 2022 and December 31, 2021, respectively, on the condensed consolidated balance sheets. A summary of the activity in contract liabilities is as follows (in thousands):

 

Balance at December 31, 2021

 

$

30,371

 

Payments received

 

 

11,065

 

Revenue recognized

 

 

(6,649

)

Medicare advance repayments

 

 

(14,538

)

Balance at June 30, 2022

 

$

20,249